Pandion Therapeutics is a clinical-stage, privately-held biotechnology company developing modular biologics (modular proteins, antibodies and bispecifics) for autoimmune and inflammatory diseases and is headquartered in Cambridge, Massachusetts. Its lead program, PT101, is an interleukin-2 (IL-2) mutein Fc fusion protein designed to potently and selectively expand regulatory T cells and is currently in a Phase 1 trial assessing safety, tolerability, pharmacokinetics and pharmacodynamic measures including regulatory T cell expansion. The company is advancing a pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. Pandion’s modular approach pairs immunomodulators such as IL-2 muteins or PD-1 agonists with tissue-selective tethers to deliver site-specific, disease-modifying immune regulation. The company closed an $80 million Series B financing to support continued development of multiple product candidates, bring a second program into the clinic, broaden its modular drug design platform, and expand team and infrastructure. The financing and board additions are intended to position Pandion to advance its lead clinical program and future candidates. Pandion Therapeutics is developing a proprietary platform of bispecific antibodies that bind specific tissues at sites of inflammation and deliver effector molecules to restore immune homeostasis while avoiding systemic immunosuppression. The company’s core product approach is tissue-specific, localized immunomodulation intended to provide durable, site-specific effects. Its initial development areas include inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions. Pandion has filed multiple patents covering its platform and applications and is translating insights from immunology and immuno-oncology into its designs. The company announced key leadership appointments (CEO Anthony J. Coyle, PhD and CSO Jo Viney, PhD) as it advances programs toward the clinic. Pandion was founded in 2017 and is headquartered in Cambridge, Massachusetts.

Total raised

$138M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2020